Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia

Evaxion announced positive preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML). The vaccine successfully expresses and secretes in human cells, drives specific immune responses across different human immune profiles, and induces targeted cell-killing. The company is preparing regulatory filings for clinical testing and will present the data at the European Hematology Association Congress in Stockholm on June 13, 2026.